Redhill Biopharma Ltd.
As of Oct 22, 2026, Redhill Biopharma is in Stage 4, the downtrend phase, now in week 15 (since Jul 10, 2026). It closed at $0.42, 75.7% below its 52-week high and below its 200-day average, which is falling.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is RDHL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
RDHL among Drug Manufacturers - Specialty & Generic70th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …70 | RDHL | Stage 4 · wk 15 | 13 | −22.3% |
Redhill Biopharma: quick answers
What stage is Redhill Biopharma in?
As of Oct 22, 2026, Redhill Biopharma (RDHL) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 10, 2026 and is in week 15. What the four stages mean
Is Redhill Biopharma in an uptrend?
No. Redhill Biopharma is in a Stage 4 downtrend. It trades 49.5% below its 200-day average, which is falling.
How far is Redhill Biopharma from its 52-week high?
Redhill Biopharma closed at $0.42 on Oct 22, 2026, 75.7% below its 52-week high of $1.74. Its 52-week low is $0.42.
How has Redhill Biopharma performed over the past year?
As of Oct 22, 2026, Redhill Biopharma is down 76.6% over the past year and down 59.0% so far in 2026.
Which sector and industry is Redhill Biopharma in?
Redhill Biopharma is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.